Screener
Palvella Therapeutics PVLA Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | $9,334 | $4,074 |
| General and administrative | 5,521 | 3,797 |
| Total operating expenses | 14,855 | 7,871 |
| Operating loss | (14,855) | (7,871) |
| Other (expense) income: | ||
| Interest expense – royalty agreement | (2,039) | (1,215) |
| Fair value adjustments on derivative liabilities – royalty agreement | (116) | (75) |
| Fair value adjustments on derivative liabilities – contingent value right liability | 202 | — |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's operating income?
- Palvella Therapeutics (PVLA) reported operating income of -$14.86M in Q1 2026.
- How has Palvella Therapeutics's operating income changed year-over-year?
- Palvella Therapeutics's operating income decreased by 88.7% year-over-year, from -$7.87M to -$14.86M.
- What is the long-term trend for Palvella Therapeutics's operating income?
- Over 2 years (2021 to 2025), Palvella Therapeutics's operating income has grown at a -13.7% compound annual growth rate (CAGR), from -$51.83M to -$38.6M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Palvella Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude